Anti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [HG-U133_Plus_2]
Summary:
Analysis of U87 human xenograft tumors (in BALB/c SCID mouse host) treated with antiangiogenic agents bevacizumab (anti-VEGF) and dibenzazepine (anti-Notch). The tumors include mouse host stroma. Results, together with those from GDS5678, provide insight into molecular basis of tumor angiogenesis.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Masiero M, Simões FC, Han HD, Snell C et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013 Aug 12;24(2):229-41. PMID: 23871637
